Highlights Surrozen, Inc.

Equities

SRZN

US86889P2083

Market Closed - Nasdaq Other stock markets 01:30:00 03/07/2024 am IST			5-day change	1st Jan Change
10.22 ^USD	-4.49%		+2.71%	+8.72%

10/06	Surrozen, Inc. Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver in Milan	CI
04/06	Surrozen Begins Dosing First Patient in Phase 1 Trial for Alcohol-Related Hepatitis Treatment	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Surrozen, Inc. Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver in Milan	10/06	CI
Surrozen, Inc. Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis	04/06	CI
Surrozen, Inc. Presents Data Demonstrating the Promise of Antibody-Based Wntimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology Annual Meeting	09/05	CI
Surrozen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Surrozen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	11/04	CI
Surrozen Provides Update on the Phase 1A Clinical Trial of SZN-043 in Healthy Volunteers and Patients with Cirrhosis	01/04	CI
Surrozen, Inc. Provides Corporate Update on Clinical Programs	18/01	CI
Surrozen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
Surrozen, Inc. Expects to Initiate A Phase 1a Clinical Trials for SZN-043 and SZN-1326 in Moderate to Severe Alcoholic Hepatitis	09/11	CI
Surrozen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10	CI
Surrozen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11	CI
Surrozen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23/23/23	CI
Tranche Update on Surrozen, Inc.'s Equity Buyback Plan announced on December 15, 2022.	15/22/15	CI
Surrozen, Inc. announces an Equity Buyback for 1,310,496 shares, for $2.7 million.	15/22/15	CI
Surrozen, Inc.'s Equity Buyback announced on December 15, 2022, has closed with 1,310,496 shares, for $2.7 million.	15/22/15	CI
Surrozen, Inc. authorizes a Buyback Plan.	12/22/12	CI
Surrozen, Inc. Updates SZN-1326, SZN-043 and SZN-413 for Vascular-Associated Retinopathies, Including Diabetic Retinopathy and Diabetic Macular Edema	16/22/16	CI
Surrozen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/22/15	CI
Surrozen, Boehringer Ingelheim to Support Research, Development of Retinal Diseases Treatment	06/22/06	MT
Surrozen, Inc. Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases	06/22/06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Surrozen, Inc.

Equities

SRZN

US86889P2083

Highlights

Filters